References
- Strausbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. Clin Chest Med 2007;28:279-88
- Cystic Fibrosis Foundation Patient Registry. 2009 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation Patient Registry, 2009
- Elphick HE, Smyth RL. Infections in patients with cystic fibrosis: effects of a longer survival. The Microbe-Host Interface in Respiratory Tract Infections. England: Horizon Scientific Press Ltd, 2004
- Govan J, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Molr Biol Rev 1996;60:539
- Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100
- Deretic V, Schurr M, Boucher J, et al. Conversion of Pseudomonas aeruginosa to mucoidy in cystic fibrosis: environmental stress and regulation of bacterial virulence by alternative sigma factors. J Bacteriol 1994;176:2773
- Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704
- Winnie GB, Cowan RG. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol 1991;10:92-100
- Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64
- Jones AM, Dodd ME, Morris J, et al. Clinical outcome for cystic fibrosis patients infected with transmissible Pseudomonas aeruginosa: an 8-year prospective study. Chest 2010;137:1405
- Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009;44:989-96
- Briggs EC, Nguyen T, Wall MC, et al. Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management; a single center experience. Clin Respir J 2011: published online 9 August 2011, doi:10.1111/j.1752-699X.2011.00246.x
- Lee T. Eradication of early Pseudomonas infection in cystic fibrosis. Chron Respir Dis 2009;6:99
- Taccetti G, Campana S, Festini F, et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005;26:458
- Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001;120(3 Suppl):107S
- Waknine Y. FDA approves inhaled aztreonam for cystic fibrosis. Medscape Today; 2010. Available at www.medscape.com/viewarticle/717553. [Last accessed 19 September 2011]
- Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212
- Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. JAMA 2003;290:1749
- U.S. Food and Drug Administration approves Cayston(R) for the improvement of respiratory symptoms in cystic fibrosis patients with pseudomonas aeruginosa. Gilead Press Release. Available at: http://www.gilead.com/pr_1393831. Accessed October 30, 2011